Phase 1 Trials of Oral GV101, a Highly Selective ROCK2 Inhibitor, in Healthy Adults

Authors
Category Primary study
Conference43rd Annual Meeting of the Obesity Society at Obesity Week
Year 2025
This article has no abstract
Epistemonikos ID: 8f987de8a41f5f365232f279ff9bdb0c70315a8b
First added on: Jan 31, 2026